Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease

NCT02596997 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-03-14

No results posted yet for this study

Summary

Provide patients with serious AdV infection or disease access to treatment with BCV.

Conditions

  • Adenovirus

Interventions

DRUG

Brincidofovir

Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week

Sponsors & Collaborators

Eligibility

Min Age
2 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02596997 on ClinicalTrials.gov